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Abstract
Background and Objectives: There is increasing evidence that galactose-deficient IgA1 (Gd-IgA1) and Gd-IgA1-containing
immune complexes are important for the pathogenesis of IgA nephropathy (IgAN). In the present study, we assessed a
novel noninvasive multi-biomarker approach in the diagnostic test for IgAN.
Materials and Methods: We compared serum levels of IgA, IgG, Gd-IgA1, Gd-IgA1-specific IgG and Gd-IgA1-specific IgA in
135 IgAN patients, 79 patients with non-IgAN chronic kidney disease (CKD) controls and 106 healthy controls. Serum was
collected at the time of kidney biopsy from all IgAN and CKD patients.
Results: Each serum marker was significantly elevated in IgAN patients compared to CKD (P,0.001) and healthy controls
(P,0.001). While 41% of IgAN patients had elevated serum Gd-IgA1 levels, 91% of these patients exhibited Gd-IgA1-specific
IgG levels above the 90th percentile for healthy controls (sensitivity 89%, specificity 92%). Although up to 25% of CKD
controls, particularly those with immune-mediated glomerular diseases including lupus nephritis, also had elevated serum
levels of Gd-IgA1-specific IgG, most IgAN patients had elevated levels of Gd-IgA1-specific antibody of both isotypes. Serum
levels of Gd-IgA1-specific IgG were associated with renal histological grading. Furthermore, there was a trend toward higher
serum levels of Gd-IgA1-specific IgG in IgAN patients with at least moderate proteinuria ($1.0 g/g), compared to patients
with less proteinuria.
Conclusions: Serum levels of Gd-IgA1-specific antibodies are elevated in most IgAN patients, and their assessment, together
with serum levels of Gd-IgA1, improves the specificity of the assays. Our observations suggest that a panel of serum
biomarkers may be helpful in differentiating IgAN from other glomerular diseases.
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Introduction
IgA nephropathy (IgAN) is the most common type of primary
glomerulonephritis worldwide [1,2]. IgAN has a significant
morbidity, culminating in end-stage kidney disease in about 40%
of patients within 20 years of diagnosis [3]. Renal biopsy is
required for the diagnosis of IgAN. Typical histological features
include granular mesangial deposits of IgA, usually accompanied
by C3, a variable presence of IgG and/or IgM, and diverse
degrees of mesangial cellular proliferation and expansion of the
extracellular matrix [4].
Several recent studies suggest that aberrant O-glycosylation of
circulatory IgA1 is vital in the pathogenesis of IgAN. The O-linked
glycans in the hinge region of IgA1 are generally composed of N-
acetylgalactosamine (GalNAc) and galactose; sialic acid may be
attached to either or both sugars. IgA1-producing cells secrete a
mixture of IgA1 O-glycofoms. Studies in different populations have
shown that IgAN patients have significantly higher levels of
circulating IgA1 with galactose-deficient, O-linked, hinge-region
glycans [5–9]. Depending on the population studied, 50–75% of
IgAN patients have levels above the 90th percentile for healthy
controls. In addition, IgA1 eluted from renal tissues of IgAN
patients also exhibits a galactose deficiency in the O-linked glycans
in the hinge-region [10,11].
The serum level of IgA1-containing circulating immune
complexes is elevated in patients with IgAN [12–14]. These
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complexes contain galactose-deficient IgA1 (Gd-IgA1) bound by
IgG and/or IgA antibodies [14,15]. Recently, we have shown that
the IgG auto-antibodies that recognize glycan-containing epitopes
on Gd-IgA1 exhibit unique features in the complementarity-
determining region 3 of the variable region of their heavy chains
[16]. Furthermore, the serum levels of IgG autoantibodies specific
for Gd-IgA1 correlated with disease severity, as assessed by
magnitude of proteinuria. However, the serum levels of Gd-IgA1-
containing circulating immune complexes may differ widely
among IgAN patients [15]. Furthermore, some IgAN patients do
not show glomerular deposition of IgG, but rather only IgA.
Therefore, it is difficult to explain the pathogenesis of IgAN by an
elevated serum level of glycan-specific antibodies of only the IgG
isotype. These latter features may be explained by our observation
that some patients with IgAN have complexes generated by
glycan-specific antibodies of the IgA1 isotype [15]. Whereas the
serum levels of IgA, Gd-IgA1 and glycan-specific IgG are higher in
patients with IgAN compared to healthy controls, the levels of
these parameters have not been systematically studied in patients
with other forms renal disease with clinical features similar to those
of IgAN. We therefore examined the prevalence of elevated serum
levels of IgA, Gd-IgA1 and glycan-specific IgG and IgA in IgAN
patients and a large cohort of CKD controls to assess the utility of
these biomarkers for the non-invasive diagnosis of IgAN. Our data
revealed that this panel of biomarkers is helpful in differentiating
patients with IgAN from patients with other glomerular diseases.
Materials and Methods
Ethics Statement
This study was performed according to the Declaration of
Helsinki and approved by the Ethics Review Committee of
Juntendo University Faculty of Medicine. All study participants
provided written informed consent.
Patients and controls
A cross-sectional study was performed using serum samples
collected at Juntendo University Hospital in Japan from 2006 to
2010 at the time of renal biopsy from 135 patients with IgAN and
79 patients with other renal diseases as shown in Table 1. We
collected serum samples from 106 healthy volunteers who had
never exhibited any abnormality by urinalysis in medical
examinations from 2009 to 2011. All patients and healthy
volunteers were Japanese, and the demographic and clinical
features are summarized in Table 2. Histological prognostic stages
of IgAN were assessed by the Clinical Guidelines for IgA
Nephropathy in Japan (second version) [17], and are as follows:
Group I: good prognosis, Group II: relatively good prognosis,
Group III: relatively poor prognosis, and Group IV: poor
prognosis.
Subgroups of disease controls
As the urinary protein/creatinine ratio in disease controls was
higher than that in IgAN patients, we divided CKD controls into
two subgroups: one with urinary protein/creatinine ratio $2.5 g/
g (high-proteinuria) and the second with urinary protein/
creatinine ratio ,2.5 g/g (low-proteinuria). Then, we compared
the levels of each biomarker between the two subgroups.
Measurement of serum biomarkers
Serum level of Gd-IgA1. The serum level of Gd-IgA1 was
measured by lectin ELISA using GalNAc-specific lectin from Helix
aspersa (HAA; Sigma, St. Louis, MO) as previously reported
[9,18,19]. Diluted sera were added 100 ng per well of serum IgA.
The captured IgA was treated with 10 mU/ml neuraminidase
(Roche Diagnostic Corp. Indianapolis, IN) to remove terminal
sialic acid residues [9,19]. The desialylated IgA1 was then reacted
with biotin-labeled HAA and subsequently developed; absorbance
was measured at 490 nm. The HAA reactivity of IgA1 in each
sample was then calculated as OD units/100 ng of serum IgA.
Naturally galactose-deficient IgA1 (Ale) myeloma protein [9]
treated with neuraminidase and was used as the standard. Serum
level of total Gd-IgA1 was expressed in relative Units, calculated
by multiplying the normalized HAA reactivity by the amount of
IgA in the serum sample (mg/ml).
Serum level of Gd-IgA1-specific IgG. ELISA plates were
coated with the Fab fragment of Gd-IgA1 myeloma protein (Ste)
generated with an IgA-specific protease from Haemophilus influenzae
HK50 [15]. The amount of total IgG used for the analyses was
normalized in all samples and added to each well. Captured IgG




Non-IgA proliferative nephropathy 9
Lupus nephritis 8
Minimal change nephrotic syndrome 6
Nephrosclerosis 4
Interstitial nephritis 2
Focal segmental glomerular sclerosis 2
ANCA-related nephritis 1
Scleroderma renal crisis 1
HCV-related nephritis 1
Fabry’s disease 1
Acute post-streptococcal nephritis 1
Minor glomerular abnormality 1
doi:10.1371/journal.pone.0098081.t001
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was detected with a biotin-labeled F(ab’)2 fragment of goat IgG
anti-human IgG antibody (BioSource; Invitrogen, San Diego, CA).
Avidin–horseradish peroxidase conjugate (ExtrAvidin; Sigma-
Aldrich) was then added, and the reaction was developed [16].
Serum levels of Gd-IgA1-specific IgG were expressed in Units (1
unit as OD 1.0 measured at 490 nm).
Serum level of Gd-IgA1-specific IgA. ELISA plates were
coated with Fab fragment of Gd-IgA1 (Ste) described above [15].
Captured antibodies were detected by incubation with mouse
monoclonal antibody to human IgA (Fc-specific) (Applied Biolog-
ical Materials Inc., Richmond, BC) and detected by Peroxidase-
conjugated AffiniPure Goat Anti-Mouse IgG (H+L) (Jackson
Immuno Research, West Grove, PA). Serum levels of Gd-IgA1-
specific IgA were expressed in Units (1 unit as OD 1.0 measured at
490 nm).
Statistical analysis
Data are expressed as means 6 SD. Comparison of groups was
performed using univariate ANOVA, and post hoc Bonferroni
correction was used for multiple comparisons. Correlation
between two groups was performed by regression analysis. P,
0.05 was considered significant. These statistical analyses were
performed using the Prism software (GraphPad Software Inc., La
Jolla, CA). The discriminatory ability of the biomarkers and
clinical data combination was estimated with the area under the
receiver operating characteristic curve (AUC-ROC). We addi-
tionally used Akaike’s Information Criterion (AIC) to select the
best predictive model [20]. The sensitivity, specificity, and positive
and negative predictive values were calculated based on the ROC
curves with the cut-off selected at the 90th percentile biomarker
value for healthy controls. We interpreted the model with the
lowest AIC as the most useful in differentiating cases from controls.
These analyses were performed with IBM SPSS Statistics release
19.0.
Results
Clinical profiles, serum IgA, IgG and Gd-IgA1
The present study was comprised of 135 IgAN patients, 79
CKD controls and 106 healthy controls (Table 2). Age, serum
creatinine concentration, and the urinary protein/creatinine ratio
were higher for the CKD controls than for IgAN patients.
The serum IgA concentration was significantly higher for the
IgAN patients (3.6061.47 mg/ml) compared to those of the CKD
controls (2.71 61.04 mg/ml, P,0.001) and healthy controls
(2.1760.75 mg/ml, P,0.001). Half of the patients with IgAN had
a serum IgA concentration higher than the 90th percentile for
healthy controls (3.06 mg/ml), consistent with a prior publication
[21]. There was no significant difference in serum IgG concen-
tration between the different groups.
Also consistent with prior reports, the serum level of Gd-IgA1
for the IgAN patients was significantly higher compared to that for
the CKD controls (P,0.001) and healthy controls (P,0.001)
(Figure 1A). Fifty-six of 135 IgAN patients (41%) but only eight
nineof 79 (11%) CKD controls had a serum Gd-IgA1 level higher
than the 90th percentile for healthy controls (P = 5.5610-7 for
differences in distribution in IgAN patients vs. CKD controls).
Serum levels of IgG and IgA antibodies against Gd-IgA1
IgAN patients had significantly higher levels of serum Gd-IgA1-
specific IgG compared with those of the CKD controls (P,0.001)
and healthy controls (P,0.001) (Figure 1B). Most IgAN patients
(123/135, 91%) had a serum level of Gd-IgA1-specific IgG higher
than the 90th percentile for healthy controls (1.48 Units). The
differences in the distribution of Gd-IgA1-specific IgG in IgAN
patients vs. disease controls were highly significant (P = 3610224).
Serum levels of Gd-IgA1-specific IgA were elevated in IgAN
patients compared with CKD controls (P,0.001) and healthy
controls (P,0.001) (0.89060.840 Units for IgAN patients, 0.482
60.483 Units for CKD controls and 0.41960.289 Units for
healthy controls; Figure 1C). The serum level of Gd-IgA1-specific
IgA was higher than the 90th percentile for healthy controls (0.611
Units) for 43% of IgAN patients and 14% of CKD controls.
While the serum levels of Gd-IgA1-specific IgG or IgA were
significantly higher in IgAN patients, about 25% of CKD controls
also had a serum level of Gd-IgA1-specific IgG higher than the
90th percentile for healthy controls. Many of IgAN patients (56/
135, 41%) had elevated levels of both Gd-IgA1-specific IgG and
IgA. In contrast, elevated levels of both IgG and IgA antibody
against Gd-IgA1 were seen in only 5 of 79 CKD controls who had
an immune- mediated glomerulonephritis, such as lupus nephritis
or membranous nephropathy (Table 3). Twenty-three of 38 CKD
controls with an immune-mediated kidney disease had an elevated
serum level of Gd-IgA1-specific IgG or IgA. In contrast, only 8 of
41 CKD controls with non-immune-mediated renal disease had an
elevated serum level of Gd-IgA1-specific IgG or IgA (p = 661024
for differences in distribution between the two groups).
Table 2. Characteristics of patients with IgAN and CKD controls.
IgAN patients CKD controls Healthy controls
Numbers 135 79 106
Age (years) 34.6611.9 50.9619.4 32.665.2
Sex (male/female) 56/79 42/37 61/45
Serum creatinine (mg/dl) 0.9360.53 2.2662.52 ND
eGFR (ml/min/1.73 m2) 76.9625.8 55.7639.2 ND
Urine P/C (g/g) 0.6560.84 3.0163.19 ND
Hematuria 4.0862.28 1.6062.23 ND
Values are mean 6SD.
eGFR, estimated glomerular filtration rate; P/C, protein/creatinine ratio; ND, not determined.
Hematuria: Assessed by assigning scores according to number of red blood cells per high-power field (RBC/HPF).
#5 RBC/HPF = 0, 6–10 RBC/HPF = 1, 11–15 RBC/HPF = 2, 16–20 RBC/HPF = 3, 21–25 RBC/HPF = 4, 26–30 RBC/HPF = 5, .30 RBC/HPF = 6.
doi:10.1371/journal.pone.0098081.t002
Serum Biomarkers for IgA Nephropathy
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Relationship between Gd-IgA1 and Gd-IgA1-specific IgG
The serum levels of Gd-IgA1-specific IgG were significantly
higher in IgAN patients with elevated Gd-IgA1 levels (P,0.001).
However, about 91% of IgAN patients with a normal serum Gd-
IgA1 level also had an elevated level of Gd-IgA1-specific IgG,
suggesting that auto-antibody production may occur independent-
ly of serum Gd-IgA1 levels (Figure 2).
Comparison of biomarker levels with clinical and
pathological findings
We assessed each biomarker for possible correlation with
histological findings and the clinical manifestations at the time of
renal biopsy. Proteinuria was inversely correlated with serum
immunoglobulin levels (IgA, and Gd-IgA1-specific IgG and IgA
autoantibodies) in CKD controls (r =20.17 to 20.28). This
Figure 1. Distribution of serum levels of (A) Gd-IgA1, (B) Gd-IgA1-specific IgG and (C) Gd-IgA1-specific IgA in patients with IgAN
(n=135), CKD controls (n =79) and healthy controls (n=106). Each biomarker was measured by capture ELISA. The serum levels of Gd-IgA,
Gd-IgA1-specific IgG and Gd-IgA1-specific IgA were higher in IgAN patients compared with those of the CKD controls (*P,0.001) and healthy
controls (**P,0.0001).
doi:10.1371/journal.pone.0098081.g001
Table 3. Serum levels of Gd-IgA1-specific antibodies in patients with IgAN, CKD controls and healthy controls.
Gd-IgA1-specific IgG (Units) Gd-IgA1-specific IgA (Units)
IgAN (N= 135) 1.7760.28 0.8960.84
Lupus nephritis WHO class III (N = 2) 1.5760.09 0.4760.26
Lupus nephritis WHO class IV (N = 4) 1.6260.19 0.4760.20
Lupus nephritis WHO class V (N = 2) 1.9160.49 0.5060.04
Membranous nephropathy (N = 9) 1.5260.19 0.4860.20
Non-IgA proliferative glomerulonephritis (N = 9) 1.4360.10 0.3660.15
Diabetic nephropathy (N = 33) 1.4360.08 0.3560.13
Nephrosclerosis (N = 4) 1.4060.07 0.4460.33
Minimal-change nephrotic syndrome (N= 6) 1.5260.27 0.6660.28
Interstitial nephritis (N = 2) 1.3360.02 0.5860.01
Other immune mediated renal diseases (N = 6) 1.4760.07 0.7160.75
Other non-immune mediated renal diseases (N = 2) 1.3960.09 0.5960.10
Healthy controls (N = 106) 1.3960.07 0.4260.29
WHO, World Health Organization.
doi:10.1371/journal.pone.0098081.t003
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association was most strongly driven by the CKD controls, who
had significantly more proteinuria than did the IgAN patients. To
assess whether the serum levels of these immunogloubulins differed
based on the magnitude of proteinuria, we divided the CKD
disease controls into high-proteinuria and low-proteinuria sub-
groups, and compared the levels of each biomarker between the
two subgroups. There was no significant difference in serum levels
of IgA, Gd-IgA1, Gd-IgA1-specific IgG, and Gd-IgA1-specific IgA
between the two subgroups (Table S1).
The serum level of Gd-IgA1-specific IgA correlated with degree
of mesangial IgA deposits in patients with IgAN (R2 = 0.61)
(Figure 3A). In addition, the histological prognostic stage
according to the clinical guidelines for IgAN in Japan [17]
correlated with proteinuria (R2 = 0.71) (Figure 3B) and the
percentage of glomeruli with crescents (R2 = 0.69) (Figure 3C).
As we previously reported [16], there was no significant
correlation between the serum levels of Gd-IgA1-specific IgG
and the degree of mesangial IgG deposition. However, there was a
trend for the serum levels of Gd-IgA1-specific IgG to be higher in
patients with greater mesangial IgG deposition (2+) (1.93760.464
Units, n = 9) than in patients with no mesangial IgG deposition
(1.74760.326 Units, n = 13). Furthermore, the mean serum level
of Gd-IgA1-specific IgG in the histological prognostic group 4
(n = 35, 1.82160.318 Units) was high, compared to that in the
histological prognostic group 1 (n = 8, 1.66360.107 Units).
Utility of biomarkers for non-invasive diagnosis of IgAN
We estimated the sensitivity and specificity of each biomarker
for prediction of IgAN, using the cut-off value of the 90th
percentile for healthy controls. The serum level of Gd-IgA1-
specific IgG performed best, providing a sensitivity of 89% and
specificity of 92% for diagnosis of IgAN. The ROC curves showed
excellent performance in comparison of IgAN vs. healthy controls
(Figure 4, with corresponding statistics summarized in Tables 4
and 5). The areas under the ROC curve (C-statistics) for anti-Gd-
IgA1 IgG were 0.965 (95%CI: 0.943–0.987) for discriminating
IgAN cases vs. healthy controls, 0.973 (95%CI: 0.948–0.999) for
non-immune-mediated CKD controls, and 0.813 (95%CI: 0.730–
0.895) for immune-mediated CKD controls. In addition, the AIC
for models testing Gd-IgA1-specific IgG were 57.4 for discrimi-
nating IgAN cases vs. healthy controls, 75.3 for non-immune-
mediated CKD controls, and 145.2 for immune-mediated CKD
controls.
These data suggest that although serum levels of Gd-IgA1-
specific autoantibodies have excellent predictive properties to
discriminate IgAN patients from healthy controls and patients with
non-immune-mediated kidney disease, the specificity is lower for
discriminating IgAN patients from patients with other types of
immune-mediated kidney disease. Altogether, elevated Gd-IgA1-
specific IgG provided positive predictive values of 92%, 96%, and
72%, and negative predictive values of 89%, 90%, and 82% for
healthy controls and patients with non-immune kidney disease,
and immune-mediated kidney disease, respectively.
Discussion
IgAN is the most common type of primary glomerulonephritis
worldwide and is often detected by urinary abnormalities, such as
microscopic hematuria and low-grade proteinuria. The clinical
features of IgAN vary between patients with IgAN. In biopsy
specimens, glomerular deposits of IgA1 are sometimes accompa-
nied by IgG and/or IgM. Although microscopic hematuria and
low-grade proteinuria are frequent laboratory findings in patients
with IgAN, some cases manifest a rapidly progressive clinical
course with crescentic glomerulonephritis while others exhibit
acute nephritic syndrome or nephrotic syndrome. The long-term
prognosis is not benign; about 40% of IgAN patients progress to
end-stage kidney disease within 20 years [3]. Thus, early diagnosis
and treatment are necessary to prevent or slow disease progres-
sion. A noninvasive approach for the diagnosis of IgAN has been
sought worldwide, especially in countries where the routine
immunohistological processing of renal biopsy tissue is prohibi-
tively expensive.
A pathway of multiple events has been proposed for the
pathogenesis of IgAN [16,22]. Immune complexes formed by the
binding of Gd-IgA1 by Gd-IgA1-specific IgG or IgA in the
circulation deposit in the mesangium and activate resident cells
[12,23–26]. Gd-IgA1-containing immune complexes from sera of
patients with IgAN induce proliferation of human mesangial cells
in culture whereas Gd-IgA1 alone does not [27,28]. Activated
mesangial cells produce inflammatory cytokines that cause
glomerular injury [29,30]. These reports suggest that Gd-IgA1-
containing immune complexes play an essential role in the
pathogenesis of IgAN. Therefore, we measured serum levels of the
key biomarkers, IgA, Gd-IgA1, Gd-IgA1-specific IgG and Gd-
IgA1-specific IgA to assess their utility in distinguishing patients
with IgAN from patients with other forms of kidney disease and
healthy controls.
The present study showed that serum levels of IgA, Gd-IgA1,
Gd-IgA1-specific IgG and Gd-IgA1-specific IgA were elevated in
patients with IgAN compared with those of healthy and CKD
controls, suggesting that these parameters may be useful for the
diagnosis of IgAN. However, several interesting limitations of these
tests have emerged.
First, elevated serum levels of Gd-IgA1 have been found in
healthy relatives of individuals with IgAN, suggesting that such
levels alone are not sufficient to cause the disease [31]. Among
patients with an established diagnosis of IgAN, the serum levels of
Gd-IgA1 are variable [9]. Notably, longitudinal trajectories of
serum Gd-IgA1 levels have not yet been established in prospective
Figure 2. Serum levels of Gd-IgA1-specific IgG in IgAN patients
with high-Gd-IgA1 or normal-Gd-IgA1 in comparison to CKD
and healthy controls. We divided IgAN patients into two subgroups:
patients with serum levels of Gd-IgA1 $ the 90th percentile for healthy
controls (high-Gd-IgA1 group; n = 56) and patients with levels Gd-IgA1
, the 90th percentile for healthy controls (normal-Gd-IgA1 group;
n = 79). Although serum levels of Gd-IgA1-specific IgG were significantly
higher in IgAN patients with high Gd-IgA1 levels (vs. CKD controls; *P,
0.0001, vs. healthy controls; **P,0.0001), IgAN patients with normal Gd-
IgA1 levels also had elevated Gd-IgA1-specific IgG (vs. CKD controls;
*P,0.0001, vs. healthy controls; **P,0.0001).
doi:10.1371/journal.pone.0098081.g002
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Figure 3. Correlation between biomarkers, histological findings and clinical findings. The strength of correlation between biomarkers,
histological findings and clinical findings was measured by the Spearman’s correlation coefficient. The serum level of Gd-IgA1-specific IgA correlated
with the amount of mesangial IgA deposits (A). Histological prognostic stage (Clinical Guidelines for IgA Nephropathy in Japan, second version) [17]
correlated with the urinary protein/creatinine ratio (B), and percentage of glomeruli with a crescent (C).
doi:10.1371/journal.pone.0098081.g003
Figure 4. Receiver operating characteristic (ROC) curves. (A) Discrimination between IgAN versus healthy and CKD controls for serum Gd-IgA1
and Gd-IgA1-specific IgG levels; (B) Discrimination between IgAN versus CKD controls with immune-mediated renal disease and non-immune-
mediated renal disease for serum Gd-IgA1-specific IgG levels.
doi:10.1371/journal.pone.0098081.g004
Serum Biomarkers for IgA Nephropathy
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cohorts of IgAN cases, and some variability may also be expected
when the diagnosis (the time of renal biopsy and serum sampling)
occurs at different stages of the disease process.
Second, in this study, we frequently observed elevated levels of
Gd-IgA1-specific autoantibodies in IgAN patients with normal
serum Gd-IgA1 levels. One potential explanation of these data is
that even when the circulating level of Gd-IgA1 is normal, there
may be a sufficient number of galactose-deficient residues on these
molecules to induce formation of pathogenic immune complexes
in the setting of elevated Gd-IgA1-specific antibodies. Further-
more, because the O-glycosylation defects may occur preferentially
at specific amino acid positions, [32] and the lectin-based assay is
not able to discriminate which sites are involved, some pathogenic
glycosylation defects may exist below the detection level of our
lectin-based method.
We also found that serum levels of Gd-IgA1-specific IgA
correlated with the intensity of mesangial IgA1 deposits, implying
that Gd-IgA1-specific IgA plays a role in glomerular deposition of
IgA1-containing immune complexes. Lastly, serum levels of Gd-
IgA1-specific IgG associated with histological grading, and we
detected a trend for higher serum levels of Gd-IgA1-specific IgG in
IgAN patients with at least moderate proteinuria ($1.0 g/g), when
compared to patients with less proteinuria. These data suggest that
Gd-IgA1-specific IgG may represent a marker of disease severity,
but its prognostic utility will require validation in independent
prospective cohorts.
We noted a substantial overlap in serum levels of individual
biomarkers between patients with IgAN, CKD controls, and
healthy controls. Consequently, no single biomarker was suffi-
ciently specific for IgAN. The levels of Gd-IgA1-specific IgG and
IgA were particularly elevated in patients with non-IgAN immune-
mediated kidney disease, such as lupus nephritis in which
increased propensity to auto-antibody production is well estab-
lished. Notably, some of these autoantibodies may be polyreactive,
i.e., binding to several autoantigens [33,34], thus complicating the
assay for IgAN. Our data raise a question as to whether the anti-
Gd-IgA1 autoantibodies in patients with lupus nephritis are
detected as an artifact of polyreactivity or constitute pathogenic
mediators of kidney injury in non-IgAN kidney disease. Additional
studies are necessary to examine this aspect of non-IgAN
glomerular diseases.
Another limitation of our study was that the CKD control group
did not contain sufficient numbers of patients with glomerular
disorders that are clinically difficult to differentiate from IgAN,
such as Alport syndrome, thin basement membrane disease, post-
infectious glomerulonephritis or membranoproliferative glomeru-
Table 4. Statistics summarized data; Discrimination between IgAN versus healthy and CKD controls for serum Gd-IgA1 and Gd-
IgA1-specific IgG levels.
Area under the ROC
curve (C-statistic)
Asymptotic 95% Confidence
Interval for the C-statistic
Asymptotic Significance
(P-value) AIC***
Lower Bound Upper Bound
Gd-IgA1-specific IgG (IgAN vs. healthy controls) 0.965 0.943 0.987 1.7E-35 57.4
Gd-IgA1-specific IgG (IgAN vs. CKD controls) 0.906 0.858 0.953 3.2E-23 188.5
Gd-IgA1-specific IgG (IgAN vs. CKD non-immune-
mediated renal disease*)
0.973 0.948 0.999 1.7E-21 75.3
Gd-IgA1-specific IgG (IgAN vs. CKD immune-
mediated renal disease**)
0.813 0.730 0.895 3.2E-10 145.2
Gd-IgA1 (IgAN vs. healthy controls) 0.800 0.745 0.855 9.9E-16 264.6
Gd-IgA1 (IgAN vs. CKD controls) 0.749 0.683 0.815 1.2E-09 246.3
Gd-IgA1-specific IgA (IgAN vs. healthy controls) 0.722 0.659 0.786 2.7E-09 295.6
Gd-IgA1-specific IgA (IgAN vs. CKD controls) 0.690 0.619 0.761 3.5E-06 266.1
* CKD non-immune-mediated renal disease includes diabetic nephropathy, nephrosclerosis, interstitial nephritis and Fabry’s disease.
** CKD immune-mediated renal disease includes lupus nephritis, membranous nephropathy, minimal change disease, membranoproliferative glomerulonephritis, other
types of non-IgAN glomerulonephritis.
***AIC: Akaike’s Information Criterion.
doi:10.1371/journal.pone.0098081.t004
Table 5. Statistics summarized data; Discrimination between IgAN versus immune-mediated CKD and non-immune-mediated CKD
controls for serum Gd-IgA1-specific IgG levels.
Sensitivity Specificity PPV NPV
Gd-IgA1-specific IgG (IgAN vs. healthy controls) 89% 92% 92% 89%
Gd-IgA1-specific IgG (IgAN vs. all CKD controls) 89% 81% 82% 88%
Gd-IgA1-specific IgG (IgAN vs. non-immune-mediated CKD) 89% 96% 96% 90%
Gd-IgA1-specific IgG (IgAN vs. immune-mediated CKD) 85% 67% 72% 82%
Gd-IgA1 (IgAN vs. healthy controls) 41% 91% 82% 61%
Gd-IgA1-specific IgA (IgAN vs. healthy controls) 34% 92% 81% 58%
PPV, Positive Predictive Value; NPV, Negative Predictive Value.
doi:10.1371/journal.pone.0098081.t005
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lonephritis. Because of the relative rarity of these conditions, large
multicenter studies will be required to validate our results in these
settings.
Conclusions
Serum levels of Gd-IgA1-specific antibodies are elevated in most
IgAN patients, even in the setting of normal serum level of Gd-
IgA1. Our study suggests that a panel of serum biomarkers may be
helpful in differentiating IgAN from other glomerular diseases.
Supporting Information
Table S1 Serum levels of biomarkers in high-protein-
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